The latest market report published by Credence Research, Inc. “Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Treatment Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2017 – 2025,” the acute bacterial skin and skin structure infections (ABSSSI) market is expected to grow at a CAGR of 9.8% from 2017 to 2025.
The purpose of the report is to illustrate the state of the market of Acute Bacterial Skin And Skin Structure Infections, to present actual information about the volumes of production, exports, imports, consumption and the state of the market, the changes that took place in 2017, and also, to build a forecast for the growth of the industry in the medium term until 2026.
Browse here for full report: https://www.credenceresearch.com/report/acute-skin-and-skin-structure-bacterial-infection-abssi-treatment-market
Request for Customization: https://www.credenceresearch.com/request-for-customization/58628
According to USFDA, acute bacterial skin and skin structure infections, or ABSSSI—includes the following criteria: accompanied by redness, edema, and/or induration of a minimum surface area of 75 cm2, accompanied by lymph node enlargement or systemic symptoms such as fever ≥38°C (100.4°F). The symptoms observed in ABSSSI are extensive cellulitis, wound infection, major cutaneous abscesses, and burn infections. ABSSSI is mainly caused due to Methicillin-susceptible Staphylococcus aureus (MSSA), Methicillin-resistant S. aureus (MRSA), Streptococcus pyogenes, Streptococcus agalactiae, Escherichia coli, Klebsiella pneumonia and Klebsiella oxytoca. According to research reports in the United States, average inpatient costs per ABSSSI patient ranges between US$6,000 to US$13,000 recorded in 2016, with multi-day room and board expenses comprising 50% of total costs. The market experts suggested that, most of the ABSSSI patients are frequently admitted to the hospital only for the administration of intravenous antibiotics.
The ABSSSI treatment market is segmented on the basis of drug type, infection type and pathogen type. In year 2016, vancomycin was observed as the leading segment in terms of revenue globally in treatment of ABSSSI due to key drivers such as most preferred molecule against multiple drug resistant bacterial infections, and certainly it has lost exclusivity which makes it affordable. However, during forecast period 2017 – 2025, delafloxacin is expected to grow at a significant rate due to key drivers such as its exclusive approval against ABSSI and high efficiency compared to existing drugs.
There are several types of ABSSSIs such as cellulitis, abscess/boil/cyst, surgical wound, and traumatic wound. In year 2016, cellulitis was observed as the largest segment due to key driving factors such as increasing prevalence of multiple drug resistant bacterial infections, mounting hospitalization of patients with chronic diseases due to high medical awareness, increasing prevalence of hospital-acquired infections, and continuous R&D activities observed in ABSSSI treatment industry.
There are several pathogens that lead to ABSSSIs such as Methicillin sensitive Staphylococcus aureus (MSSA), Methicillin resistant Staphylococcus aureus (MRSA), Beta-hemolytic Streptococcus, Escherichia coli, Enterococcus faecalis, Pseudomonas aeruginosa, and others. In year 2016, MRSA & MSSA were observed as the largest segments and accounted for more than 50% of the total market share due to key drivers such as rising prevalence of multi-resistance bacterial infections, high public awareness associated with hospital acquired infections, and incessant research and development in field of ABSSSI treatment. According to American Pharmacists Association, approximately 3 million patients hospitalized each year in the U.S. with ABSSSI often present treatment challenges owing to their underlying medical conditions, making optimal antibiotic selection difficult.
9.1. Furiex Pharmaceuticals, Inc.
9.1.1. Business Description
9.1.2. Financial Information (Subject to data availability)
9.1.3. Product Portfolio
9.1.4. Key Developments
9.2. GlaxoSmithKline plc
9.3. Melinta Therapeutics, Inc.
9.4. Debiopharm International S.A.
9.5. MerLion Pharmaceuticals Pte Ltd.
9.6. Durata Therapeutics, Inc.
9.7. Paratek Pharmaceuticals, Inc.
9.8. Cempra, Inc.
9.9. Abbott Laboratories, Inc.
9.10. Actelion Pharmaceuticals Ltd.
9.11. Albany Molecular Research, Inc.
9.12. Allergan plc.
9.14. Bayer AG
9.15. Macrolide Pharmaceuticals, Inc.
9.16. Merck & Co, Inc.
9.17. Pfizer, Inc.
9.19. Teva Pharmaceuticals Industries Ltd.
9.20. Zavante Therapeutics, Inc.
Why was the report written?
This report is the result of an extensive survey drawn from Credence Research’s exclusive panel of leading global market industry executives; it provides data and analysis on buyer investment, acquisition, and developments within the global market research. It includes key topics such as global Acute Bacterial Skin And Skin Structure Infections buyer expenditure and procurement behaviors and strategies and recognizes the threats and possibilities within the industry, economic outlook trends, and business confidence within global industry executives. Most secondary research reports are based on general industry drivers and do not understand the industry executives’ attitude and changing behaviors, creating a gap in presenting the business outlook of the industry; in an effort to bridge this gap, Credence Research created this primary research-based report by gathering the opinions of multiple stakeholders in the value chain of the global industry.
What is the current market landscape and what is changing?
Executives from the global industry anticipate an increase in levels of consolidation, with 55% of respondents projecting an increase in merger and acquisition (M&A) activities in 2017.
The report on the market of Acute Bacterial Skin And Skin Structure Infections contains:
Analysis and forecast of Acute Bacterial Skin And Skin Structure Infections market dynamics;
Analysis of domestic production, market shares of the main market players;
Analysis of exports and imports;
Analysis of factors, leading the development of the Acute Bacterial Skin And Skin Structure Infections market;
Assessment and forecast of Acute Bacterial Skin And Skin Structure Infections market development;
Financial and business profiles of the leading companies in the Acute Bacterial Skin And Skin Structure Infections industry.
– Up to date working Acute Bacterial Skin And Skin Structure Infections data by major regions in the world, the forecast of planned capacity additions by 2026
– The annual breakdown of capital expenditure spending on proposed Acute Bacterial Skin And Skin Structure Infections for the period 2018 to 2026
– Planned Acute Bacterial Skin And Skin Structure Infections additions and capital expenditure spending by key countries and companies across the world
– Planned capital expenditure spending on new Acute Bacterial Skin And Skin Structure Infections projects by region, key countries, and companies
– Details of major planned Acute Bacterial Skin And Skin Structure Infections projects in the world up to 2026
Also you can request us for sample in pdf with more details and graph: https://www.credenceresearch.com/sample-request/58628
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Credence Research Inc.
105 N 1st ST #429
Toll Free (US/CANADA): +1-800-361-8290